Review



breast cancer index  (NSABP Foundation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    NSABP Foundation breast cancer index
    Breast Cancer Index, supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+index/breast+cancer+index++bci+/pm39602125-137-100-63
    Average 90 stars, based on 1 article reviews
    breast cancer index - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Biomarker Discovery:

    Article Title: A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
    Article Snippet: .. The resulting score ranges from 0 to 10 and designates patients as having a low or high risk of recurrence.11 An analysis of patients from the TransATAC study (International Standard Randomized Controlled Trial Number 18233230) showed that the Breast Cancer Index was prognostic for both early and late recurrences but suggested that this assay was particularly useful for the prediction of late recurrences in years 5 to 10 after initial diagnosis.31 Data from the MA.17 trial (ClinicalTrials. gov identifier NCT00003140) and the aTTom trial (ClinicalTrials.gov identifier NCT00003678) demonstrated that the Breast Cancer Index was predictive for benefit from extended adjuvant therapy in patients with node- negative or node- positive, HR- positive early breast cancer.32,33 In contrast, the Breast Cancer Index was not predictive for benefit from extended letrozole in patients with HR- positive, HER2- negative early breast cancer in a recent analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B- 42 trial (ClinicalTrials.gov identifier NCT00382070).34 ..

    Adjuvant:

    Article Title: A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
    Article Snippet: .. The resulting score ranges from 0 to 10 and designates patients as having a low or high risk of recurrence.11 An analysis of patients from the TransATAC study (International Standard Randomized Controlled Trial Number 18233230) showed that the Breast Cancer Index was prognostic for both early and late recurrences but suggested that this assay was particularly useful for the prediction of late recurrences in years 5 to 10 after initial diagnosis.31 Data from the MA.17 trial (ClinicalTrials. gov identifier NCT00003140) and the aTTom trial (ClinicalTrials.gov identifier NCT00003678) demonstrated that the Breast Cancer Index was predictive for benefit from extended adjuvant therapy in patients with node- negative or node- positive, HR- positive early breast cancer.32,33 In contrast, the Breast Cancer Index was not predictive for benefit from extended letrozole in patients with HR- positive, HER2- negative early breast cancer in a recent analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B- 42 trial (ClinicalTrials.gov identifier NCT00382070).34 ..

    Derivative Assay:

    Article Title: Dissecting Biological Risk Using Genomic Assays-Implications for Extended Endocrine Therapy and Beyond.
    Article Snippet: .. Patients with tumors with a high Breast Cancer Index derived significant EET benefit for RFI and DFI (identical end point to BCFI here), whereas those with tumors with a low Breast Cancer Index did not benefit.31 Similar results were observed in the NCIC CTG MA-1732 and aTTom trials,33 leading to the Breast Cancer Index’s inclusion in the NCCN Guidelines.10 In the recently published NSABP B-42 translational analysis, high vs low Breast Cancer Index did not show statistically significant difference in extended letrozole therapy benefit for the primary end point of RFI.49 However, in time-dependent analysis for DR, patients with high Breast Cancer Index showed significant EET benefit after 4 years. .. In the NSABP B-42 trial, patients with 70-gene assay–classified low-risk tumors showed significant extended letrozole therapy benefit for DR and BCFI.49 In the IDEAL and NSABP B-42 trials, both the 70-gene expression risk-of-recurrence assay and Breast Cancer Index have the ability to identify a subset of patients of approximately 45% who benefit from EET.



    Similar Products

    breast cancer index  (bioTheranostics)
    90
    bioTheranostics breast cancer index
    Breast Cancer Index, supplied by bioTheranostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+index/breast+cancer+index/pm40644891-344-1-5
    Average 90 stars, based on 1 article reviews
    breast cancer index - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    selectivity index four breast cancer cell lines  (ATCC)
    99
    ATCC selectivity index four breast cancer cell lines
    Selectivity Index Four Breast Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+index/MCF7/pm40596939-45-3-18
    Average 99 stars, based on 1 article reviews
    selectivity index four breast cancer cell lines - by Bioz Stars, 2026-11
    99/100 stars
    		  Buy from Supplier
    breast cancer index  (Immunomedics inc)
    90
    Immunomedics inc breast cancer index
    Breast Cancer Index, supplied by Immunomedics inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+index/breast+cancer+index/pmc11637582-273-6-10
    Average 90 stars, based on 1 article reviews
    breast cancer index - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    breast cancer index (bci) test  (bioTheranostics)
    90
    bioTheranostics breast cancer index (bci) test
    Breast Cancer Index (Bci) Test, supplied by bioTheranostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+index/breast+cancer+index/pm39602119-10-1-5
    Average 90 stars, based on 1 article reviews
    breast cancer index (bci) test - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    breast cancer index  (NSABP Foundation)
    90
    NSABP Foundation breast cancer index
    Breast Cancer Index, supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+index/breast+cancer+index++bci+/pm39602125-137-100-63
    Average 90 stars, based on 1 article reviews
    breast cancer index - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    breast cancer index (bci)  (NSABP Foundation)
    90
    NSABP Foundation breast cancer index (bci)
    Breast Cancer Index (Bci), supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+index/nsabp+b+18/pmc11061597__ccr___23___1977_supplementary_figure_s1_suppfs1-1-39-43
    Average 90 stars, based on 1 article reviews
    breast cancer index (bci) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results